B. Findlay

12.7k citations

44 papers · 9.1k indexed · 2 hit papers · h-index 25

Impact in

Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes

Papers in ⓘ

Oncology 37
- Cancer Treatment and Pharmacology 18
- Colorectal Cancer Treatments and Studies 17
- Lung Cancer Research Studies 5
- Cancer survivorship and care 4
Cancer Research 10
- Breast Cancer Treatment Studies 9

Co-authors: Richard M. Goldberg (19 shared papers)Daniel J. Sargent (18 shared papers)Roscoe F. Morton (17 shared papers)Charles S. Fuchs (16 shared papers)Stephen K. Williamson (17 shared papers)Ramesh K. Ramanathan (11 shared papers)Frances A. Shepherd (5 shared papers)Lesley Seymour (4 shared papers)
Journals: Journal of Clinical Oncology (24 papers)Cancer (3 papers)European Journal of Cancer (3 papers)Annals of Oncology (2 papers)JNCI Journal of the National Cancer Institute (1 paper)
Partner nations: Canada United States New Zealand

In The Last Decade

B. Findlay

44 papers receiving 8.8k citations

Hit Papers

align trajectories log scale

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer 2005 · 4.3k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2005 New England Journal of Medicine
2003 Journal of Clinical Oncology

Peers

Countries citing papers authored by B. Findlay

Since Specialization

Citations

This map shows the geographic impact of B. Findlay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Findlay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Findlay more than expected).

Fields of papers citing papers by B. Findlay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Findlay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Findlay. The network helps show where B. Findlay may publish in the future.

Co-authors

The 25 scholars most cited alongside B. Findlay, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with B. Findlay Line = papers co-authored together B. Findlay links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Erlotinib in Previously Treated Non–Small-Cell Lung Cancer New England Journal of Medicine ·Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel de Castro, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano Van Kooten, Mircea Dediu, B. Findlay, Dongsheng Tu, D. Johnston, Andrea Bezjak, Gary M. Clark, P. Santabárbara, Lesley Seymour Hit paper breakdown →	2005	4281
2	A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer Journal of Clinical Oncology ·Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, B. Findlay, Henry C. Pitot, Steven R. Alberts Hit paper breakdown →	2003	1818
3	Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology ·Mark N. Levine, V. Bramwell, Kathleen I. Pritchard, B. Norris, Lois E. Shepherd, Hakam Abu-Zahra, B. Findlay, David Warr, David M. J. S. Bowman, James D. Myles, Andrew Arnold, Ted Vandenberg, Robert G. MacKenzie, J Robert, J. Ottaway, Margot J. Burnell, Christopher Kwesi O. Williams, Dan‐Na Tu	1998	442
4	Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10 Journal of Clinical Oncology ·Charles Butts, Keyue Ding, Lesley Seymour, Philip Twumasi‐Ankrah, Barbara Graham, David R. Gandara, David H. Johnson, Kenneth A. Kesler, Mark A. Green, Mark Vincent, Yvon Cormier, Greg G. Goss, B. Findlay, Michael Johnston, Ming‐Sound Tsao, Frances A. Shepherd	2009	295
5	Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741 Journal of Clinical Oncology ·Hanna K. Sanoff, Daniel J. Sargent, Megan E. Campbell, Roscoe F. Morton, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, B. Findlay, Henry C. Pitot, Richard M. Goldberg	2008	241
6	Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17 Journal of Clinical Oncology ·Edith A. Perez, Robert G. Josse, Kathleen I. Pritchard, James N. Ingle, Silvana Martino, B. Findlay, Tamara Shenkier, Richard Tozer, Michael Palmer, Lois E. Shepherd, Shifang Liu, Dongsheng Tu, Paul E. Goss	2006	233
7	Quality of life in stage II breast cancer: an instrument for clinical trials. Journal of Clinical Oncology ·Mark N. Levine, Gordon Guyatt, Michael Gent, Sonja De Pauw, Michael Goodyear, W M Hryniuk, Andrew Arnold, B. Findlay, Jamey Skillings, V. Bramwell	1988	175
8	Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial Journal of Clinical Oncology ·Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, B. Findlay, Henry C. Pitot, Steven R. Alberts	2006	173
9	Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741 Journal of Clinical Oncology ·Howard L. McLeod, Daniel J. Sargent, Sharon Marsh, Erin M. Green, Cristi R. King, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, B. Findlay, Stephen N. Thibodeau, Axel Grothey, Roscoe F. Morton, Richard M. Goldberg	2010	170
10	Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20 Journal of Clinical Oncology ·Andrew Arnold, Lesley Seymour, Michael Smylie, Keyue Ding, Yee Ung, B. Findlay, Christopher W. Lee, Marina Djurfeldt, Marlo Whitehead, Peter Ellis, Glenwood Goss, Adrien Chan, J. Meharchand, Yasmin Alam, Richard Gregg, Charles Butts, Peter Langmuir, Frances A. Shepherd	2007	157
11	Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial JNCI Journal of the National Cancer Institute ·Nicole Mittmann, H. Au, D. Tu, Christopher J. O’Callaghan, Pierre K. Isogai, Christos S. Karapetis, John Zalcberg, W.K. Evans, M. J. Moore, J. Siddiqui, B. Findlay, Brian Colwell, John Simes, Peter Gibbs, Matthew Links, Niall C. Tebbutt, Derek J. Jonker	2009	122
12	Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741 Annals of Oncology ·Thierry Delaunoit, Steven R. Alberts, Daniel J. Sargent, E. Green, Richard M. Goldberg, James E. Krook, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, Roscoe F. Morton, B. Findlay	2005	120
13	Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial Journal of Clinical Oncology ·Pamela J. Goodwin, Roanne Segal, Michael Vallis, Jennifer A. Ligibel, Gregory R. Pond, André Robidoux, George L. Blackburn, B. Findlay, Julie R. Gralow, Som D. Mukherjee, Mark N. Levine, Kathleen I. Pritchard	2014	119
14	Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8 Journal of Clinical Oncology ·B. Norris, Kathleen I. Pritchard, K. James, James D. Myles, Katherine Bennett, Sébastien Marlin, Jamey Skillings, B. Findlay, Ted Vandenberg, Paul E. Goss, Jean Latreille, Leona Rudinskas, W. Lofters, Maureen Trudeau, David Osoba, A. Rodgers	2000	118
15	Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14 Journal of Clinical Oncology ·Kathleen I. Pritchard, Lois E. Shepherd, Judith‐Anne W. Chapman, B. Norris, Jacques Cantin, Paul E. Goss, Susan Dent, David Walde, Ted Vandenberg, B. Findlay, Susan E. O’Reilly, Carolyn F. Wilson, Lei Han, Ettie Piura, Timothy J. Whelan, Michaël Pollak	2011	66
16	Mortality associated with daily bolus 5‐fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin Cancer ·Thierry Delaunoit, Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, B. Findlay, Sachdev Thomas, Muhammad Salim, Paul Schaefer, Philip J. Stella, Erin Green, James A. Mailliard	2004	61
17	Impact of Complete Response to Chemotherapy on Overall Survival in Advanced Colorectal Cancer: Results From Intergroup N9741 Journal of Clinical Oncology ·Grace K. Dy, James E. Krook, Erin M. Green, Daniel J. Sargent, Thierry Delaunoit, Roscoe F. Morton, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, B. Findlay, Barbara A. Pockaj, Robert P. Sticca, Steven R. Alberts, Henry C. Pitot, Richard M. Goldberg	2007	49
18	A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. Journal of Clinical Oncology ·Mark N. Levine, Michael Gent, W M Hryniuk, V. Bramwell, Hakam Abu-Zahra, Sonja Depauw, Andrew Arnold, B. Findlay, L Levin, Jamey Skillings	1990	47
19	N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study Journal of Clinical Oncology ·Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, R. K. Ramanathan, Stephen K. Williamson, B. Findlay, H. Pitot, Steven R. Alberts	2004	43
20	Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy Supportive Care in Cancer ·Jean Latreille, Dave Stewart, Francis Laberge, Paul Hoskins, James J. Rusthoven, Elissa McMurtrie, David Warr, Louise Yelle, David Walde, Frances A. Shepherd, Harbhajan Dhaliwal, B. Findlay, D. Le Mée, D. Johnston	1995	37

About B. Findlay

B. Findlay is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Pediatrics, Perinatology and Child Health, having authored 44 papers that have together received 9.1k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (17 papers), Breast Cancer Treatment Studies (9 papers), Gastric Cancer Management and Outcomes (8 papers), Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (5 papers), Cancer survivorship and care (4 papers) and Childhood Cancer Survivors' Quality of Life (4 papers). The work is most often cited by research in Oncology (7.0k citations), Pulmonary and Respiratory Medicine (4.8k citations), Hepatology (1.0k citations), Cancer Research (1.5k citations) and Pathology and Forensic Medicine (672 citations). B. Findlay has collaborated with scholars based in Canada, United States and New Zealand. Frequent co-authors include Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, Stephen K. Williamson, Ramesh K. Ramanathan, Frances A. Shepherd, Lesley Seymour, Henry C. Pitot and Dongsheng Tu. Their work appears in journals such as Journal of Clinical Oncology, Cancer, European Journal of Cancer, Annals of Oncology and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact